Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Rodrigues DN, et al. Among authors: rescigno p. J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. J Clin Invest. 2018. PMID: 30382943 Free PMC article. No abstract available.
Elucidating Durable Responses to Immune Checkpoint Inhibition.
Rescigno P, Aversa C, Crespo M, Seed G, Lambros M, Gurel B, Figueiredo I, Bianchini D, Riisnaes R, Pereira R, Fenor de la Maza MD, Carmichael J, Chandran K, Ferreira A, Bertan C, Paschalis A, Curcean A, Sharp A, Yuan W, Tunariu N, Poehlein C, Carreira S, de Bono JS. Rescigno P, et al. Eur Urol. 2020 Oct;78(4):639-641. doi: 10.1016/j.eururo.2020.06.056. Epub 2020 Jul 9. Eur Urol. 2020. PMID: 32653323 No abstract available.
Non-AIDS-related Kaposi's sarcoma: A single-institution experience.
Rescigno P, Di Trolio R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G. Rescigno P, et al. World J Clin Oncol. 2013 May 10;4(2):52-7. doi: 10.5306/wjco.v4.i2.52. World J Clin Oncol. 2013. PMID: 23696963 Free PMC article.
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.
Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudioso G, Terracciano D, Di Trolio R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R. Di Lorenzo G, et al. Among authors: rescigno p. J Transl Med. 2013 Jul 2;11:161. doi: 10.1186/1479-5876-11-161. J Transl Med. 2013. PMID: 23819610 Free PMC article.
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Perez-Lopez R, et al. Among authors: rescigno p. Radiology. 2017 Apr;283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22. Radiology. 2017. PMID: 27875103 Free PMC article. Clinical Trial.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garcés T, Pacheco MI, Flohr P, Massard C, López-Casas PP, Castro E, de Bono JS, Olmos D. Lozano R, et al. Among authors: rescigno p. Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334. Cancers (Basel). 2021. PMID: 34066080 Free PMC article.
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H. Shenoy TR, et al. Among authors: rescigno p. Ann Oncol. 2017 Jul 1;28(7):1495-1507. doi: 10.1093/annonc/mdx165. Ann Oncol. 2017. PMID: 28383660 Free PMC article.
118 results